Astrana Health (NASDAQ:ASTH) Price Target Cut to $45.00 by Analysts at BTIG Research

Astrana Health (NASDAQ:ASTH) had its target price cut by stock analysts at BTIG Research from $50.00 to $45.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s target price would indicate a potential upside of 76.19% from the stock’s current price.

ASTH has been the topic of several other research reports. Zacks Research upgraded shares of Astrana Health from a “strong sell” rating to a “hold” rating in a research report on Friday, October 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Astrana Health in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Astrana Health presently has an average rating of “Moderate Buy” and an average price target of $47.00.

Astrana Health Price Performance

Shares of ASTH traded down $7.82 on Friday, hitting $25.54. The company’s stock had a trading volume of 1,199,426 shares, compared to its average volume of 346,841. The company has a market capitalization of $1.43 billion, a PE ratio of 50.08, a PEG ratio of 0.90 and a beta of 0.80. Astrana Health has a fifty-two week low of $21.20 and a fifty-two week high of $57.42. The company has a 50 day moving average price of $30.57 and a 200 day moving average price of $27.96. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.59 and a quick ratio of 1.59.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings data on Wednesday, January 10th. The company reported $0.50 earnings per share (EPS) for the quarter. The firm had revenue of $317.00 million during the quarter. Astrana Health had a return on equity of 3.43% and a net margin of 1.04%. On average, research analysts anticipate that Astrana Health will post 1.15 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Astrana Health

Several hedge funds have recently added to or reduced their stakes in the stock. Bastion Asset Management Inc. acquired a new position in shares of Astrana Health during the 3rd quarter worth about $604,000. Public Sector Pension Investment Board grew its stake in Astrana Health by 18.3% in the third quarter. Public Sector Pension Investment Board now owns 167,490 shares of the company’s stock valued at $4,748,000 after acquiring an additional 25,949 shares during the period. Linden Thomas Advisory Services LLC increased its holdings in shares of Astrana Health by 4.4% in the third quarter. Linden Thomas Advisory Services LLC now owns 28,665 shares of the company’s stock worth $813,000 after acquiring an additional 1,199 shares in the last quarter. Diamond Hill Capital Management Inc. raised its holdings in Astrana Health by 33.0% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 361,264 shares of the company’s stock worth $10,242,000 after buying an additional 89,733 shares during the period. Finally, Savant Capital LLC raised its holdings in shares of Astrana Health by 2.2% during the third quarter. Savant Capital LLC now owns 30,713 shares of the company’s stock worth $871,000 after acquiring an additional 649 shares during the period. Institutional investors and hedge funds own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.